Technical analysis of Jasper Therapeutics, Inc. (JSPR): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells.
Price Performance
| 1 month | -22.07% |
| 3 months | +29.03% |
| Year-to-date | -68.06% |
| 1 year | -74.91% |
| 3 years | -92.64% |
| 5 years | -99.41% |
52-Week Range
| 52-week High | $2.69 |
| 52-week Low | $0.32 |
| Avg Volume (90d) | 1.2M |
Technical Indicators
| SMA 50 | $0.70 |
| SMA 200 | $1.04 |
| Beta | 3.20 |
| 30-day Volatility (annualised) | 90.1% |
| Price vs SMA 50 | -16.8% |
| Price vs SMA 200 | -44.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.28 | |
| 2025-11 | $1.84 | -19.3% |
| 2025-12 | $1.83 | -0.5% |
| 2026-01 | $1.48 | -19.1% |
| 2026-02 | $1.38 | -6.8% |
| 2026-03 | $0.88 | -36.5% |
| 2026-04 | $0.94 | +6.8% |
| 2026-05 | $0.83 | -11.4% |
| 2026-06 | $0.42 | -49.2% |
| 2026-07 | $0.63 | +49.6% |
| 2026-08 | $0.71 | +12.9% |
| 2026-09 | $0.58 | -17.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $0.58 |
| Market Cap | $9M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 11.94 |
| EV / EBITDA | -0.14 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.19 |
| Current Ratio | 1.47 |
| Piotroski F-Score | 0 |
| Altman Z-Score | -18.43 |